ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November… Read More..

As SKYX Continues to Enhance its Market Penetration, it will Showcase its Patented Game-Changing Smart Home Platform Technology to Over 4,000 High-End Real-Estate Developers and Industry Professionals MIAMI, FL / ACCESSWIRE / November 2, 2023 / SKYX Platforms Corp. (NASDAQ:SKYX) (d/b/a "SKYX Technologies"), a highly disruptive platform technology company with… Read More..

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - Fast Track Designation Accelerates SLS009's Path to U.S. FDA Submission for Treatment of r/r PTCL - NEW… Read More..